Furthermore, PαS MSC treatment inhibited not only acute lung injury but additionally suppressed expansion of pro-inflammatory T helper subsets expressing IL-17 and IFN-γ in the post-acute pneumonia phase. The gene discussed is IL17A; the disease is pneumonia.